HIV p55

HIV p55 Full Name

Human immunodeficiency virus type 1 Gag p55

HIV p55 Introduction

The HIV-1 p55 Gag precursor is a 55-kDa polyprotein that serves as the major structural scaffold for virion assembly. It encompasses multiple functional domains, including the matrix (MA/p17), capsid (CA/p24), nucleocapsid (NC/p7), and p6 regions, interspersed with SP1 and SP2 spacer peptides. Proteolytic cleavage by the viral protease during maturation produces the mature structural proteins p17, p24, p7, and p15/p14, which form the organized virion core. The MA domain, containing an N-terminal myristoyl group and a basic patch, directs plasma membrane targeting and contributes to envelope incorporation, positioning p55 as the central driver of virion assembly and structural organization. Monoclonal antibody mapping and biochemical analyses indicate that p55-derived species display a multiphasic maturation profile, reflecting its dynamic role during virion assembly and structural reorganization.

Beyond structural scaffolding, p55 Gag orchestrates interactions with host cellular membranes and factors, regulating both virus assembly and intracellular trafficking. Its MA domain mediates association with lipid rafts and detergent-resistant membranes, ensuring proper recruitment of envelope glycoproteins to budding sites. The dynamic localization of p55 in cytoplasmic and membrane-associated compartments facilitates the coordinated incorporation of viral components, including envelope glycoproteins, into nascent virions. In addition, p55 interacts with other viral proteins and cellular factors, influencing complex formation and assembly intermediates, and its structural integrity directly affects the efficiency of virion maturation and infectivity. Experimental studies also highlight p55's potential to modulate host cellular pathways in vitro, such as mesenchymal stem cell differentiation and osteogenesis, demonstrating that Gag can influence host biology beyond its structural role.

p55 Gag is a highly immunogenic antigen and a valuable vaccine target due to its capacity to elicit robust cellular immune responses. Virus-like particles (VLPs) or replicon-based platforms presenting full-length p55 induce strong, broad, and long-lived CD8+ T cell responses, with recognition of multiple naturally processed epitopes. Vaccination strategies focusing on conserved regions within the p24 domain further broaden the T cell response, enhancing both CD4+ and CD8+ populations. Particulate presentation of p55, as opposed to soluble protein, significantly improves immunogenicity, highlighting the importance of structural context in vaccine design. Overall, p55 Gag integrates structural, functional, and immunogenic roles: it directs virion assembly, regulates envelope incorporation, modulates host pathways in vitro, and provides a key antigenic target for vaccine strategies, establishing it as central to HIV-1 replication, maturation, and immune intervention strategies.

Alternate Names for HIV p55

HIV-1 Gag p55; Human immunodeficiency virus type 1 Gag p55

• 1. He W., et al. IFI27 inhibits HIV-1 replication by degrading Gag protein through the ubiquitin-proteasome pathway. Journal of Virology. 2024;98(11).
  2. Kalams S., et al. Focusing HIV-1 Gag T cell responses to highly conserved regions by DNA vaccination in HVTN 119. Jci Insight. 2024;9(18).
  3. Zhang Z., et al. Characterization and epitope mapping of a panel of monoclonal antibodies against HIV-1 matrix protein. Biotechnology and Applied Biochemistry. 2018;65(6):807-815.